Posters
Presenting Author Academic/Professional Position
Jose J Loayza Pintado / Resident Physician PGY2
Academic Level (Author 1)
Resident
Discipline/Specialty (Author 2)
Internal Medicine
Academic Level (Author 3)
Resident
Discipline Track
Clinical Science
Abstract Type
Research/Clinical
Abstract
Introduction: Menopause is associated with significant physiological changes, including alterations in lipid profiles. Estrogen therapy plays a crucial role in managing symptoms and preventing long-term complications. This study aims to compare oral and transdermal routes of estrogen therapy among postmenopausal women and assess changes in lipid parameters from baseline.
Methods: Randomized clinical trials comparing oral and transdermal estrogen therapy in postmenopausal women were identified through searches in PubMed, Scopus, Web of Science, and ClinicalTrials.gov. Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Statistical analysis was conducted using R version 4.3.2.
Results: Eight randomized clinical trials, comprising 885 participants, were included in the analysis. Of these, 453 participants (51.2%) received oral estrogen therapy. Participants on oral estrogen therapy showed a significantly higher mean increase in high-density lipoprotein (HDL) levels (MD = 3.48 mg/dL; 95% CI, 1.54 to 5.43; p < 0.01) and a notable rise in triglyceride levels (MD = 19.82 mg/dL; 95% CI, 6.85 to 32.78; p < 0.01) compared to those on transdermal estrogen therapy. No significant differences were found in the mean changes in total cholesterol and low-density lipoprotein (LDL) levels.
Conclusions: Oral estrogen therapy, compared to transdermal administration, resulted in a greater increase in high-density lipoprotein (HDL) levels, but also a more pronounced rise in triglyceride levels in postmenopausal women. These findings highlight the importance of tailoring estrogen therapy to individual patients, considering their baseline hormonal and metabolic profiles, especially lipid parameters, to optimize treatment outcomes and minimize cardiovascular risks.
Presentation Type
Poster
Recommended Citation
Doma, Mohamed; Loayza Pintado, Jose J.; Atwal, Aria; Lopez Jesus, Angelica; Zahrawi, Farhaan; Saleh, Ibrahim; El Gammal, Ahmed; Maharm, Zeyad; Galal Ramadan, Adham; Vlassis, Benito; Shafeeq Ali, Mustafa; Khodr Aljamali, Mohammad; Pandey, Ralph; Mefti, Mounira; Badran, Merhan; Aslam, Muaaz; Subedi, Anuj; Shah, Jaffer; and Aiash, Hani, "Comparing the Effect of Oral and Transdermal Estrogen Therapy on Lipid profile in Postmenopausal Women: A Systematic Review and Meta-analysis of Randomized Clinical Trials" (2026). Research Colloquium. 114.
https://scholarworks.utrgv.edu/colloquium/2025/posters/114
Included in
Comparing the Effect of Oral and Transdermal Estrogen Therapy on Lipid profile in Postmenopausal Women: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Introduction: Menopause is associated with significant physiological changes, including alterations in lipid profiles. Estrogen therapy plays a crucial role in managing symptoms and preventing long-term complications. This study aims to compare oral and transdermal routes of estrogen therapy among postmenopausal women and assess changes in lipid parameters from baseline.
Methods: Randomized clinical trials comparing oral and transdermal estrogen therapy in postmenopausal women were identified through searches in PubMed, Scopus, Web of Science, and ClinicalTrials.gov. Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Statistical analysis was conducted using R version 4.3.2.
Results: Eight randomized clinical trials, comprising 885 participants, were included in the analysis. Of these, 453 participants (51.2%) received oral estrogen therapy. Participants on oral estrogen therapy showed a significantly higher mean increase in high-density lipoprotein (HDL) levels (MD = 3.48 mg/dL; 95% CI, 1.54 to 5.43; p < 0.01) and a notable rise in triglyceride levels (MD = 19.82 mg/dL; 95% CI, 6.85 to 32.78; p < 0.01) compared to those on transdermal estrogen therapy. No significant differences were found in the mean changes in total cholesterol and low-density lipoprotein (LDL) levels.
Conclusions: Oral estrogen therapy, compared to transdermal administration, resulted in a greater increase in high-density lipoprotein (HDL) levels, but also a more pronounced rise in triglyceride levels in postmenopausal women. These findings highlight the importance of tailoring estrogen therapy to individual patients, considering their baseline hormonal and metabolic profiles, especially lipid parameters, to optimize treatment outcomes and minimize cardiovascular risks.
